ACE launches second annual Canada’s Best Workplaces for Employees Living with Arthritis program
Canadian employers, working with their private health insurers, are increasingly looking for ways to promote patient-focused prevention, treatment and management of arthritis as part of a health and wellness program for employees. To recognize these best arthritis practices, Arthritis Consumer Experts (ACE) announces the second annual search for Canada’s Best Workplaces for Employees Living with Arthritis.
Categorizing companies by size (small, medium and large), ACE analyzes company practices and programs compared to other candidate companies based on criteria such as arthritis literacy, physical workplace adaptability, flexible hours and extended health benefit plans.
To determine if your company is eligible for Canada’s Best Workplaces for Employees Living with Arthritis program, please visit: jointhealth.org.
Subsequent entry biologics (SEBs) are a “hot topic” in health care today. They are a new class of medications entering the Canadian marketplace and consumers and patients living with autoimmune forms of arthritis and other diseases affecting the immune system need to learn about them from credible sources.
Arthritis Consumer Experts and the JointHealth™ family of education programs is pleased to offer you the latest facts on SEBs from leading patient educator and advocate:
Ms. Cheryl Koehn
Founder and President, Arthritis Consumer Experts
To register for the “SEB Facts” webinar, please complete the form. Please complete all fields marked * and click “submit”.
You will receive 2 reminder emails as the broadcast date nears.
Thank you for registering for Arthritis Consumer Experts’ “SEB facts” Webinar.
One of the busiest times of year in arthritis, and here’s what ACE has been working on.
Alberta Election Candidate Survey
ACE sent an open letter and survey to all candidates in the May 5th Alberta provincial election, asking them how their Party plans to improve arthritis prevention, treatment and care for more than 500,000 Albertans living with the disease. To see the survey and candidate responses, please go to jointhealth.org.Continue reading →
Common Drug Review recommendation for tofacitinib (Xeljanz®)
Good news for Canadians living with rheumatoid arthritis
On April 21, 2015, the Common Drug Review concluded its review of tofacitinib (Xeljanz®) and recommended to public formularies that it be listed for reimbursement in combination with methotrexate (MTX), for reducing the signs and symptoms of rheumatoid arthritis (RA) in adult patients with moderately to severely active RA or as a monotherapy in those who were intolerant to MTX. Click here to read the complete Common Drug Review recommendations. Continue reading →
Do you have psoriatic arthritis or care for someone who does? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for apremilast (Otezla®) for the treatment of psoriatic arthritis. Apremilast is an oral, small-molecule compound, taken as one tablet twice a day. The medication works by inhibiting the action of phosphodiesterase-4 (PDE4). PDE4 is an enzyme found in immune cells.
The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec). Continue reading →
ACE goes to Saskatoon for the 2015 CADTH Symposium
Making arthritis news: Sharing the latest from the Paris of the Prairies
Arthritis Consumer Experts (ACE) will be in Saskatoon, the “Paris of the Prairies”, to attend the 2015 CADTH Symposium at TCU Place. The meeting, between Sunday, April 12 and Tuesday, April 14, will bring together producers and users of evidence-based information on drugs and health technologies to learn about, collaborate and share the latest advances in health research and care. Each year, the symposium attracts an estimated 650 delegates from key sectors, including Health Technology Assessment (HTA) producers, health economists, government, universities, healthcare providers, industry and patient groups. Continue reading →